Net Profit Margin
since 2005
Calculation
Bristol-Myers Squibb Co., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net earnings (loss) attributable to BMS1 | ÷ | Revenues1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | -18.53% | = | 100 | × | (8,948) | ÷ | 48,300) |
| Dec 31, 2023 | 17.83% | = | 100 | × | 8,025) | ÷ | 45,006) |
| Dec 31, 2022 | 13.71% | = | 100 | × | 6,327) | ÷ | 46,159) |
| Dec 31, 2021 | 15.08% | = | 100 | × | 6,994) | ÷ | 46,385) |
| Dec 31, 2020 | -21.20% | = | 100 | × | (9,015) | ÷ | 42,518) |
| Dec 31, 2019 | 13.15% | = | 100 | × | 3,439) | ÷ | 26,145) |
| Dec 31, 2018 | 21.81% | = | 100 | × | 4,920) | ÷ | 22,561) |
| Dec 31, 2017 | 4.85% | = | 100 | × | 1,007) | ÷ | 20,776) |
| Dec 31, 2016 | 22.94% | = | 100 | × | 4,457) | ÷ | 19,427) |
| Dec 31, 2015 | 9.45% | = | 100 | × | 1,565) | ÷ | 16,560) |
| Dec 31, 2014 | 12.62% | = | 100 | × | 2,004) | ÷ | 15,879) |
| Dec 31, 2013 | 15.64% | = | 100 | × | 2,563) | ÷ | 16,385) |
| Dec 31, 2012 | 11.12% | = | 100 | × | 1,960) | ÷ | 17,621) |
| Dec 31, 2011 | 17.46% | = | 100 | × | 3,709) | ÷ | 21,244) |
| Dec 31, 2010 | 15.92% | = | 100 | × | 3,102) | ÷ | 19,484) |
| Dec 31, 2009 | 56.42% | = | 100 | × | 10,612) | ÷ | 18,808) |
| Dec 31, 2008 | 25.47% | = | 100 | × | 5,247) | ÷ | 20,597) |
| Dec 31, 2007 | 11.19% | = | 100 | × | 2,165) | ÷ | 19,348) |
| Dec 31, 2006 | 8.85% | = | 100 | × | 1,585) | ÷ | 17,914) |
| Dec 31, 2005 | 15.62% | = | 100 | × | 3,000) | ÷ | 19,207) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
- Net Earnings (Loss) Attributable to BMS
- Net earnings displayed considerable volatility throughout the observed period. The figure peaked notably in 2009 at 10,612 million USD, followed by a decline and fluctuating values until 2014. A significant resurgence is observed in 2016 and 2018 with values of 4,457 million USD and 4,920 million USD respectively. However, a sharp decline led to a net loss of 9,015 million USD in 2020. Recovery occurred again in the subsequent years, with positive earnings recorded until 2023. The latest data point in 2024 shows another substantial loss of 8,948 million USD, indicating ongoing instability in net profitability.
- Revenues
- Revenues demonstrated a generally positive trend over the two decades. Beginning at 19,207 million USD in 2005, revenues fluctuated slightly but maintained a moderate growth trajectory, crossing 20,000 million USD in 2013 and continuing upward. A remarkable surge is evident in 2020, with revenues reaching 42,518 million USD, more than doubling from 2019. Revenues remained stable with marginal fluctuations around the 45,000 million USD mark through 2024, with the latest figure at 48,300 million USD, signaling strong top-line growth despite volatility in net earnings.
- Net Profit Margin
- The net profit margin mirrored the volatility observed in net earnings. Early years showed moderate margins, with a peak of 56.42% in 2009, which is notably high and suggests exceptional earnings performance that year. After 2009, margins decreased and showed fluctuations, generally ranging between approximately 4.85% and 22.94% until 2019. Negative margins were recorded in 2020 (-21.2%) and again in 2024 (-18.53%), aligning with the reported net losses in these years. Overall, the margin profile indicates periods of strong profitability interspersed with significant losses, reflecting variability in operational efficiency or extraordinary items impacting net income.
Comparison to Competitors
Bristol-Myers Squibb Co., net profit margin, long-term trends, comparison to competitors
| Bristol-Myers Squibb Co. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | -18.53% | 7.59% | 12.77% | 16.33% | 23.51% | 1.68% | 15.84% | 26.68% | 12.62% | 31.07% | 14.77% | -4.86% |
| Dec 31, 2023 | 17.83% | 8.95% | 24.96% | 19.94% | 15.36% | 21.03% | 41.28% | 0.61% | 3.56% | 30.14% | 13.99% | 36.68% |
| Dec 31, 2022 | 13.71% | 20.39% | 26.42% | 22.91% | 21.88% | 17.02% | 18.90% | 24.49% | 31.01% | 35.64% | 15.47% | 37.20% |
| Dec 31, 2021 | 15.08% | 20.54% | 24.25% | 21.84% | 19.71% | 23.05% | 22.26% | 26.79% | 26.76% | 50.25% | 19.70% | 30.92% |
| Dec 31, 2020 | -21.20% | 10.08% | 29.97% | 16.36% | 25.24% | 0.51% | 17.82% | 14.72% | 22.53% | 41.35% | 19.79% | 43.70% |
| Dec 31, 2019 | 13.15% | 23.69% | 35.32% | 16.80% | 37.27% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% | 28.27% |
| Dec 31, 2018 | 21.81% | 17.36% | 37.25% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 68.80% |
| Dec 31, 2017 | 4.85% | 18.82% | 9.08% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 10.59% |
| Dec 31, 2016 | 22.94% | 23.22% | 35.27% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | -6.58% |
| Dec 31, 2015 | 9.45% | 22.50% | 33.13% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | -53.89% |
| Dec 31, 2014 | 12.62% | 8.89% | 26.69% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | -127.25% |
| Dec 31, 2013 | 15.64% | 21.97% | 27.93% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | -36.72% |
| Dec 31, 2012 | 11.12% | 28.70% | 26.11% | 13.10% | 18.09% | 27.57% | 16.14% | 13.05% | 24.70% | 54.43% | 9.42% | -7.01% |
| Dec 31, 2011 | 17.46% | — | 24.08% | 13.50% | 17.90% | 34.60% | 14.87% | 13.05% | 14.84% | -49.74% | 11.34% | 2.10% |
| Dec 31, 2010 | 15.92% | — | 31.56% | 13.58% | 21.97% | 39.26% | 21.65% | 1.87% | 12.18% | -22.76% | 9.60% | -526.35% |
| Dec 31, 2009 | 56.42% | — | 32.09% | 10.30% | 19.82% | 40.74% | 19.82% | 47.04% | 17.27% | -17.88% | 8.41% | -630.27% |
| Dec 31, 2008 | 25.47% | — | 28.57% | 10.38% | -10.17% | 39.55% | 20.31% | 32.74% | 16.78% | -34.69% | 9.47% | -262.02% |
| Dec 31, 2007 | 11.19% | — | 22.12% | 12.42% | 15.85% | 43.27% | 17.31% | 13.54% | 16.82% | -84.46% | 7.81% | -196.61% |
| Dec 31, 2006 | 8.85% | — | 21.29% | 11.69% | 16.97% | -45.98% | 20.73% | 19.59% | 39.98% | -161.30% | 4.46% | -95.63% |
| Dec 31, 2005 | 15.62% | — | 30.56% | 11.24% | 13.52% | 44.99% | 20.61% | 21.04% | 15.76% | -144.19% | 8.48% | -126.43% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Bristol-Myers Squibb Co., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Bristol-Myers Squibb Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | -18.53% | 12.30% |
| Dec 31, 2023 | 17.83% | 17.95% |
| Dec 31, 2022 | 13.71% | 22.55% |
| Dec 31, 2021 | 15.08% | 23.38% |
| Dec 31, 2020 | -21.20% | 14.07% |
| Dec 31, 2019 | 13.15% | 23.22% |
| Dec 31, 2018 | 21.81% | 19.82% |
| Dec 31, 2017 | 4.85% | 13.06% |
| Dec 31, 2016 | 22.94% | 20.78% |
| Dec 31, 2015 | 9.45% | 21.17% |
| Dec 31, 2014 | 12.62% | 21.24% |
| Dec 31, 2013 | 15.64% | 21.99% |
| Dec 31, 2012 | 11.12% | 18.53% |
| Dec 31, 2011 | 17.46% | 15.70% |
| Dec 31, 2010 | 15.92% | 15.16% |
| Dec 31, 2009 | 56.42% | 25.73% |
| Dec 31, 2008 | 25.47% | 18.17% |
| Dec 31, 2007 | 11.19% | 15.90% |
| Dec 31, 2006 | 8.85% | 22.24% |
| Dec 31, 2005 | 15.62% | 18.33% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Bristol-Myers Squibb Co., net profit margin, long-term trends, comparison to industry (health care)
| Bristol-Myers Squibb Co. | Health Care | |
|---|---|---|
| Dec 31, 2024 | -18.53% | 7.02% |
| Dec 31, 2023 | 17.83% | 9.24% |
| Dec 31, 2022 | 13.71% | 11.62% |
| Dec 31, 2021 | 15.08% | 12.42% |
| Dec 31, 2020 | -21.20% | 8.45% |
| Dec 31, 2019 | 13.15% | 11.58% |
| Dec 31, 2018 | 21.81% | 9.92% |
| Dec 31, 2017 | 4.85% | 8.05% |
| Dec 31, 2016 | 22.94% | 10.68% |
| Dec 31, 2015 | 9.45% | 11.77% |
| Dec 31, 2014 | 12.62% | 12.15% |
| Dec 31, 2013 | 15.64% | 12.81% |
| Dec 31, 2012 | 11.12% | 11.86% |
| Dec 31, 2011 | 17.46% | 10.50% |
| Dec 31, 2010 | 15.92% | 10.48% |
| Dec 31, 2009 | 56.42% | 15.08% |
| Dec 31, 2008 | 25.47% | 11.35% |
| Dec 31, 2007 | 11.19% | 11.02% |
| Dec 31, 2006 | 8.85% | 13.95% |
| Dec 31, 2005 | 15.62% | 13.38% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).